Dexamethasone sustained-release - Taiwan Liposomal Company

Drug Profile

Dexamethasone sustained-release - Taiwan Liposomal Company

Alternative Names: TLC 599

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Corticosteroids; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 11 Jul 2017 Taiwan Liposomal Company receives US patent covering dexamethasone sustained-release
  • 16 Mar 2017 Phase-II clinical trials in Osteoarthritis (In the elderly, In adults) in Australia and Taiwan (Intra-articular) (NCT03005873)
  • 03 Jan 2017 Taiwan Food and Drug Administration approves IND application for a phase II trial of TLC 599 in Osteoarthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top